Enzo Biochem Inc. | Ownership
Companies that own Enzo Biochem Inc.
Evermore Global Advisors LLC
4,747,904
10.07%
-50,000
2.91%
06/30/2018
Wellington Management Co. LLP
4,642,041
9.84%
80,135
0%
06/30/2018
BlackRock Fund Advisors
3,398,098
7.21%
287,125
0%
06/30/2018
Renaissance Technologies LLC
3,002,200
6.37%
25,300
0.01%
06/30/2018
The Vanguard Group, Inc.
2,064,357
4.38%
149,870
0%
06/30/2018
Dimensional Fund Advisors LP
2,002,571
4.25%
-17,079
0%
06/30/2018
Manulife Asset Management (US) LLC
1,706,578
3.62%
1,689,271
0.01%
06/30/2018
American Investors Advisors, Inc.
1,216,196
2.58%
0
91.04%
12/31/2017
Gilder, Gagnon, Howe & Co. LLC
763,219
1.62%
-293,181
0.04%
06/30/2018
SSgA Funds Management, Inc.
738,702
1.57%
19,359
0%
06/30/2018
| Address |
60 Executive Boulevard
New York New York 11735
United States
|
|
Employees
|
- |
| Website |
http://www.enzo.com |
| Updated |
07/08/2019 |
| Enzo Biochem, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines target the following conditions: inflammatory bowel disease, uveitis, human immunodeficiency virus, diabetes, and bone disorders. The company was founded by Elazar Rabbani, Barry W. |
